Abstract
The mechanism of action of hepatitis B immunoglobulin (HBIG) for chronic hepatitis B (CHB) treatment is not fully understood. A clinical trial in Japan suggested that HBIG therapy might benefit patients with CHB.1 Lenvervimab, a recombinant monoclonal HBIG developed by GC Pharma (Yongin, South Korea), has been screened from an anti–HBs-enriched phage-display library cloned from hepatitis B vaccine-boosted human blood cells and was produced in Chinese hamster ovary cells.2–4
Original language | English |
---|---|
Pages (from-to) | 3043-3045.e1 |
Journal | Clinical Gastroenterology and Hepatology |
Volume | 18 |
Issue number | 13 |
DOIs | |
Publication status | Published - 2020 Dec |
Bibliographical note
Funding Information:Funding Supported by GC Pharma Co Ltd.
All Science Journal Classification (ASJC) codes
- Hepatology
- Gastroenterology